Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Eight RNAi-Related Patent Applications: Sep 18, 2008

Premium
Title: Compositions and Methods of RNAi Therapeutics for Treatment of Cancer and Other Neovascularization Diseases
 
Number: 20080220027
 
Filed: June 29, 2007
 
Lead Inventor: Yijia Liu, Intradigm
 
According to the patent application’s abstract, the invention comprises “compositions and methods … for [the] treatment of diseases involving unwanted neovascularization. The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues.
 
The abstract adds that the patent application claims “tissue-targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.”
 

 
Title: Oligonucleotide Probes Useful for Detection and Analysis of microRNA Precursors
 
Number: 20080220423
 
Filed: May 17, 2007
 
Lead Inventor: Soren Moller, Exiqon
 
The invention, the patent application’s abstract states, “relates to ribonucleic acids and oligonucleotide probes useful for detection and analysis of microRNA precursors and their targets. The invention furthermore relates to oligonucleotide probes for detection and analysis of other non-coding RNAs, mRNAs, mRNA splice variants, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts, e.g., alterations associated with human disease, such as cancer.”
 

 
Title: Inhibiting Gene Expression with dsRNA
 
Number: 20080221054
 
Filed: Oct. 31, 2007
 
Lead Inventor: Magdalena Zernicka-Goetz, Cancer Research Technology
 
According to the patent application’s abstract, the invention “relates to the specific inhibition of gene expression in mammals by bringing the target gene into contact with double-stranded RNA.”
 

 
Title: Compositions and Methods for Inhibiting Expression of Huntingtin Gene
 
Number: 20080221055
 
Filed: Nov. 26, 2007
 
Lead Inventor: Dinah Wen-Yee Sah, Alnylam Pharmaceuticals
 
“The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of the huntingtin gene, comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene,” according to the patent application’s abstract. “The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.”
 

 
Title: Novel Treatment Tool for Cancer: RNA Interference of BCAS2
 
Number: 20080221059
 
Filed: April 3, 2008
 
Lead Inventor: Show-Li Chen, National Taiwan University
 
The invention, the patent application’s abstract states, “provides three BCAS2 related nucleotide sequences … [and] provides a composition comprising a nucleotide sequence of small interfering RNA of BCAS2 gene. The … invention further provides a method for treating p53 containing cancer comprising administrating a subject with an effective amount of the said composition.”
 

 
Title: siRNA Targeting Ethanolamine Kinase 11
 
Number: 20080221316
 
Filed: June 5, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to EKI1.”
 

 
Title: siRNA Targeting Cystic Fibrosis Transmembrane Conductance Regulator
 
Number: 20080221317
 
Filed: July 25, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CFTR.”
 

 
Title: RNA Interference and Disease Resistance in Avians
 
Number: 20080222743
 
Filed: May 1, 2007
 
Lead Inventor: Leandro Christmann, Avigenics
 
“The invention,” the patent application’s abstract states, “relates to transgenic avians whose genome contains nucleotide sequences which encode therapeutic polynucleotides that correspond to one or more certain sequences in the genome of an avian pathogen.”

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.